Drugs / AQ280
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07093008 | Jun → Jul 2025 | eosinophilic esophagitis | AQILION AB | Completed | No outcome recorded |
| Phase 1 | NCT05485779 | Jul 2022 → Jul 2023 | eosinophilic esophagitis | AQILION AB | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-03-20 | AQILION AB | Results Aqilion to Present Preclinical Data at Digestive Disease Week, May 2–5, Demonstrating That AQ280 Counteracts Dysfunctional Epithelial Barrier Function in Eosinophilic Esophagitis aqilion.com ↗
The study demonstrates effects that are unique to AQ280 compared with competing, already established treatments. |
| 2025-10-16 | AQILION AB | Results Positive Results from Clinical Pharmacokinetic Study for the Eosinophilic Esophagitis Specific Formulation with the Drug Candidate AQ280 aqilion.com ↗
Aqilion today announces positive results from the ARIA-2 clinical study. |
| 2025-05-12 | AQILION AB | Regulatory Aqilion receives IND approval from FDA aqilion.com ↗
AQILION AB (publ) today announces that the US Food and Drug Administration (FDA) has approved Aqilion's IND (investigational new drug ) application for the drug candidate AQ280. |
| 2023-10-30 | AQILION AB | Results Aqilion reports positive results from the ARIA-1 Phase 1 study in healthy subjects aqilion.com ↗
AQILION (publ) reports positive results from its Phase 1 study ARIA-1 in healthy volunteers with the drug candidate AQ280, a selective proprietary JAK1 inhibitor, being developed as a treatment for eosinophilic esophagitis (EoE) within the Regulus program. |
| 2022-06-15 | AQILION AB | Regulatory Aqilion resolves on issue in kind aqilion.com ↗
The Board has therefore resolved on the issue today according to the agreement, since the Phase I clinical trial was approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK. |
| 2022-06-14 | AQILION AB | Regulatory Aqilion receives regulatory approval to conduct Phase 1 clinical trial in Regulus program within inflammatory diseases aqilion.com ↗
Aqilion is announcing today that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has approved the company’s Phase 1 clinical trial with its drug candidate AQ280. |
All press releases naming this drug 10 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AQ280 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05485779 ↗ |
| Route | Oral | “Method of administration: oral” NCT05485779 ↗ |